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Abstract The Tat protein of human immunode¢ciency virus
type 1 (HIV-1) trans-activates HIV-1 transcription by function-
ally interacting with a number of cellular proteins, among which
the Sp1 transcription factor. We recently demonstrated that Tat
does not directly interact with Sp1 either in vitro or in vivo, and
we suggested that other protein(s) could indirectly mediate Tat^
Sp1 interaction. In keeping, here we showed that addition of
HeLa cell nuclear extracts to puri¢ed Tat and Sp1 proteins
allows the formation of a Tat/Sp1 complex in in vitro binding
assays. In an attempt to identify the partner(s) that bridge Tat
and Sp1, we developed a yeast multi-protein system, in which
cellular proteins recently shown to play a relevant role in Tat
function, namely TATA box-binding protein, cyclin T1, CDK9,
and cyclin T1/CDK9 complex, were coexpressed, individually or
in pair-wise combination, with Tat and Sp1 hybrids. We dem-
onstrated that none of these candidate partners bridges Tat and
Sp1. However, our yeast multi-protein system, which allows
simple and rapid detection of interactions among up to four
proteins, will be most helpful to further dissect the interaction
of Tat and Sp1 with other candidate partners that participate in
the assembly of transcriptionally active complexes at the HIV-1
LTR.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Tat protein of the human immunode¢ciency virus type
1 (HIV-1) is a powerful trans-activator of viral gene expres-
sion and is essential for HIV-1 replication [1]. Tat acts by
binding the Tat-responsive region (TAR) of HIV-1 long ter-
minal repeat (LTR) and by functionally interacting with a
number of proteins, among which the Sp1 cellular transcrip-
tion factor [2]. Sp1 is a 95^105-kDa protein, ubiquitously
expressed in mammalian cells, that modulates transcription
initiation through interaction with other proteins, called
coactivators [3]. Several reports suggest that interaction be-
tween Sp1 and Tat is required for Tat-mediated HIV-1 LTR
trans-activation [4^7]; however, the mechanistic puzzle of how
Tat^Sp1 functional interaction enhances HIV-1 transcription
has not yet been explained.
Exploiting both biochemical and genetic techniques that
allow detection of direct protein^protein interactions, we re-
cently demonstrated that HIV-1 Tat protein does not physi-
cally interact with Sp1 both in vitro and in vivo, and we
suggested that other protein(s) could indirectly mediate Tat^
Sp1 interaction [8]. A number of cellular proteins have been
reported to interact with Tat, including Tat-binding protein 1
[9], TATA box-binding protein (TBP) [10,11], TBP-associated
factor TAFII55 [12], HT2A [13], Tip60 [14], cyclin T1 (CycT1)
[15], Puralpha [16], and many others. Also Sp1 has been
shown to interact with several proteins, including TBP [17],
dTAFII110/hTAFII130 [18], YY1 [19], Oct-1 [20], E2F [21]
and the retinoblastoma-related protein p107 [22]. Any of these
proteins, other cellular protein(s) or HIV-1-encoded protein(s)
could indirectly mediate Tat^Sp1 interaction.
In this report, we investigated whether a component of
mammalian nuclei could indeed mediate the interaction of
Tat with Sp1 in in vitro assays with HeLa cell nuclear ex-
tracts. Moreover, by means of the yeast two-hybrid system
we assayed the interaction of Tat and Sp1 with cellular pro-
teins shown to play a relevant role in Tat function, namely
TBP, CycT1, cyclin-dependent kinase 9 (CDK9) and the
CycT1/CDK9 complex. Finally, to test whether any of these
proteins might be able to bridge Tat and Sp1, we developed a
yeast multi-protein system that allows detection of interac-
tions among up to four protein partners. Our experiments
dissect some key protein^protein interactions involved in the
assembly of transcription complexes at the HIV-1 LTR and
thus could contribute to a better understanding of the puz-
zling mechanism of HIV-1 replication.
2. Materials and methods
2.1. Constructs
The construction of LexA-Tat, LexA-Sp1, GAD-Tat, GAD-Sp1,
Tat-LexA, Sp1-LexA, LexA-TBP, GAD-TBP, LexA-CycT1, and
GAD-CycT1 fusion proteins (encoded by pBTM-Tat, pBTM-Sp1,
pACT-Tat, pACT-Sp1, pNLexA-Tat, pNLexA-Sp1, pBTM-TBP,
pACT-TBP, pBTM-CycT1, and pACT-CycT1 plasmid, respectively)
has been previously described [8]. To create pBTM-CDK9 and pACT-
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CDK9 plasmids, expressing the LexA-CDK9 and GAD-CDK9 hy-
brids, respectively, the CDK9 coding sequence was ampli¢ed from
pBS-CDK9 (kindly supplied by X. Grana, Temple University, Phila-
delphia, PA, USA) with primers 5P-AACGCAGGATCCAAGTGG-
CAAAGCAGTACGAC-3P (forward) and 5P-ACACTAGTCGACT-
CAGAAGACGCGCTCAAA-3P (reverse), and cloned into BamHI/
SalI sites of pBTM116 [23] and into BamHI/XhoI sites of pACTII
(gift of D. Shore, Columbia University, New York, NY, USA), re-
spectively. TBP, CycT1 and CDK9 coding sequences were also cloned
into the yeast expression vector pMYK (a gift from A. Pallavicini,
University of Padua, Italy), a derivative of pHybLex/Zeo (Invitrogen),
where the HindIII fragment, expressing LexA, was excised. The
pMYK vector contains a strong, constitutive alcohol dehydrogenase
(ADH1) promoter and transcription terminator driving the expression
of downstream cloned genes, and the zeocin resistance gene allowing
selection of both bacterial and yeast transformed strains. pMYK-TBP
was created by amplifying TBP coding sequence from pKB104 (pro-
vided by A.J. Berk, Molecular Biology Institute, University of
California, Los Angeles, CA, USA) with primers 5P-AACGAAG-
GATCCATGGATCAGAACAACAGC-3P (forward) and 5P-TCT-
CTAATGCATGTCGACTTACGTCGTCTTCCTGAA-3P (reverse),
and cloning the BamHI/SalI fragment into BglII/SalI sites of
pMYK. pMYK-CycT1 was generated by amplifying the CycT1 cod-
ing sequence from pGEX2T-cyclin T (a gift from L. Lania, Depart-
ment of Genetics, General and Molecular Biology, University of
Naples ‘Federico II’, Naples, Italy) with primers 5P-TGAATCG-
GATCCATGGAGGGAGAGAGGAAG-3P (forward) and 5P-TTCA-
TCGTCGACTTACTTAGGAAGGGGTGG-3P (reverse), and clon-
ing the BamHI/SalI fragment into BglII/SalI sites of pMYK.
pMYK-CDK9 was constructed by amplifying the CDK9 coding se-
quence from pBS-CDK9 with primers 5P-ACAACCGGATCCATGG-
CAAAGCAGTACGAC-3P (forward) and 5P-ACACTAGTCGACT-
CAGAAGACGCGCTCAAA-3P (reverse), and cloning the BamHI/
SalI fragment into BglII/SalI sites of pMYK. Finally, the pAL-
CDK9 plasmid was created by amplifying the ade2 marker gene under
its own promoter (nucleotides 2170^4686) from pMET A (Invitrogen)
with primers 5P-GTCACAGGATCCTTCGGATTCATGCTTATG-3P
(forward) and 5P-CATCACGGATCCGATCTTATGTATGAAATT-
C-3P (reverse), and cloning the BamHI fragment into the BamHI
site of pMYK-CDK9. All recombinant plasmids were sequenced
with an ABI Prism1 310 Genetic Analyzer (Perkin Elmer, Boston,
MA, USA).
2.2. Yeast manipulation and L-galactosidase assays
The yeast strain Saccharomyces cerevisiae CTY10-5d (MATa ade2-1
trp1-901 leu2-3,112 his3-200 gal4 gal80 URA3: :lexA op-lacZ) contains
the lacZ reporter gene, integrated at the URA3 locus, with eight bind-
ing sites for LexA dimers upstream of the transcription start site [23].
Growth media and standard methods for manipulating yeast cells
were as described by Rose et al. [24]. S. cerevisiae CTY10-5d was
transformed with plasmid DNA by the lithium acetate method of
Schiestl and Giest [25]. Transformed cells were assayed for expression
of the lacZ reporter gene by X-Gal ¢lter assays as described [26].
Reporter gene activity was tested on all transformed clones.
2.3. Yeast multi-protein assays
To test multi-protein interactions, the yeast strain CTY10-5d con-
taining Tat and Sp1 two-hybrid plasmids was grown in media lacking
leucine and tryptophan or histidine, and transformed with a third
plasmid, derived from pMYK. Transformed yeast cells were selected
in the presence of zeocin (300 Wg/ml, from Cayla) on plates lacking
leucine, tryptophan or histidine. In addition, triple transformants ex-
pressing Tat and Sp1 hybrids plus CycT1 in a non-fused form were
transformed with a fourth plasmid, pAL-CDK9, and selected in the
presence of zeocin onto synthetic minimal media lacking leucine, tryp-
tophan or histidine, and adenine. Transformed yeast cells were tested
for expression of the lacZ reporter gene as described above.
2.4. In vitro binding assays
In vitro binding assays between Tat and Sp1 were performed as
described [8]. The maltose-binding protein (MBP)-Tat fusion protein
(MBP-Tat) used in these assays was puri¢ed as reported [27]. Re-
combinant human Sp1 was purchased from Promega. In some sam-
ples, nuclear extracts from HeLa cells, prepared as previously de-
scribed [28], were added.
3. Results
3.1. Analysis of HIV-1 Tat and Sp1 interaction in vitro in the
presence of cell nuclear extracts
We recently reported that puri¢ed HIV-1 Tat protein does
not physically interact with human recombinant Sp1 (rhSp1)
in vitro, and we suggested that other cellular protein(s) could
indirectly mediate Tat-Sp1 interaction in vivo [8]. To test this
hypothesis, an in vitro binding assay between Tat and Sp1 in
the presence of nuclear extracts from HeLa cells was per-
formed. Puri¢ed MBP-Tat fusion protein was incubated
with rhSp1, in the presence or in the absence of HeLa cell
nuclear extracts. Samples were retrieved by an amylose resin
and analysed for the presence of Tat and Sp1 by Western blot
analysis. As shown in Fig. 1, MBP-Tat did not bind rhSp1 in
the absence of nuclear extracts, as we previously reported [8].
In contrast, a complex between Tat and Sp1 could be detected
when HeLa cell nuclear extracts were incubated with puri¢ed
MBP-Tat and rhSp1, as revealed by Western blot analysis
Table 1
Analysis of the interaction of Tat and Sp1 with cellular proteins by
the yeast two-hybrid system
Hybrid L-Gal
expressiona
DNA-binding
domain fusion
Activation domain
fusion
LexA-TBP 3b
GAD-TBP 3b
LexA-TBP GAD-TBP 3
LexA-Tat GAD-TBP +b
Tat-LexA GAD-TBP +b
LexA-TBP GAD-Tat +b
LexA-Sp1 GAD-TBP +b
Sp1-LexA GAD-TBP +b
LexA-TBP GAD-Sp1 +b
LexA-CycT1 3b
GAD-CycT1 3b
LexA-CycT1 GAD-CycT1 +
LexA-Tat GAD-CycT1 +b
Tat-LexA GAD-CycT1 +b
LexA-CycT1 GAD-Tat +b
LexA-Sp1 GAD-CycT1 3
Sp1-LexA GAD-CycT1 3
LexA-CycT1 GAD-Sp1 3
LexA-CDK9 3
GAD-CDK9 3
LexA-CDK9 GAD-CDK9 3
LexA-Tat GAD-CDK9 3
Tat-LexA GAD-CDK9 Q
LexA-CDK9 GAD-Tat 3
LexA-Sp1 GAD-CDK9 3
Sp1-LexA GAD-CDK9 3
LexA-CDK9 GAD-Sp1 3
LexA-RAP1 3
GAD-RIF1 3
LexA-RAP1 GAD-RIF1 +
TBP, CycT1 or CDK9 coding sequences were fused to the C-termi-
nus of LexA (DNA-binding domain) or of GAL4 activation domain
(GAD), and assayed for interaction with Tat and Sp1 hybrids by
L-Gal assays as described in Section 2. As a positive control for
protein^protein interaction, yeast cells were transformed with plas-
mids encoding the LexA-RAP1 (repressor-activator protein 1) and
GAD-RIF1 (RAP1 interacting factor 1) hybrid proteins, that were
previously shown to interact [36].
a(+) Strong blue colour detected after 3^5 h incubation; ( Q ) light
blue colour detected after 8^12 h incubation; (3) no signal detected
after 24 h incubation.
bData previously reported [8].
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with speci¢c anti-Tat (Fig. 1A) and anti-Sp1 antibodies (Fig.
1B). Moreover, a complex between Tat and endogenous Sp1
could also be detected when HeLa cell nuclear extracts were
incubated with puri¢ed MBP-Tat alone, as previously re-
ported [28].
These data provide further evidence that Sp1 does not di-
rectly contact Tat, and that a molecule(s) present in mamma-
lian nuclei indeed mediates Tat^Sp1 interaction.
3.2. Analysis of the interaction of Tat and Sp1 with candidate
cellular partners by yeast two-hybrid and three-hybrid
systems
The above results suggest that one or more cellular pro-
tein(s) could mediate Tat^Sp1 interaction in a multi-protein
complex. We previously demonstrated, by fusing TBP to
LexA and GAD and testing its interaction with Tat and
Sp1 by means of the yeast two-hybrid system, that TBP binds
both Tat and Sp1 ([8] ; see also Table 1), con¢rming previous
reports [10,11,17]. Therefore, to determine whether TBP may
promote interaction between Tat and Sp1, we developed a
yeast three-protein system allowing detection of Z-protein-
mediated X/Y interactions. TBP was cloned in the pMYK
yeast expression vector, to allow its expression in a non-fused
form, and transfected into yeast clones containing the Tat and
Sp1 two-hybrid plasmids. As shown in Table 2, all the Tat/
TBP/Sp1 combinations yielded negative results, suggesting
that TBP alone does not bridge Tat^Sp1 interaction. A slight
expression of L-Gal was observed in yeast clones producing
Tat-LexA and GAD-Sp1 hybrid proteins; however, as we
previously reported [8], this expression was comparable to
that of control cells producing the Tat-LexA fusion protein
alone.
Other cellular proteins that may bridge Tat and Sp1 are
CycT1 and CDK9, since the CycT1/CDK9 complex was re-
cently shown to play a key role in Tat-mediated trans-activa-
tion of HIV-1 LTR [15,29]. Therefore, we tested whether
CycT1 and/or CDK9 interact with Tat and Sp1 by means
of the yeast two- and three-hybrid systems. The results of
the two-hybrid system indicate that CycT1 interacts with
Tat, as we and others previously reported [8,15], but not
with Sp1, whereas CDK9 does not bind either Tat or Sp1
(Table 1). The slight expression of L-Gal observed in yeast
clones producing Tat-LexA and GAD-CDK9 fusion proteins
was again due to background trans-activating activity of the
Tat-LexA hybrid. Interestingly, we also observed that CycT1
dimerises.
The results of the three-protein system with CycT1 and
CDK9 were negative (Table 2), indicating that neither
CycT1 nor CDK9 alone mediates Tat-Sp1 interaction. In con-
trast, expression of CycT1 in an unfused form, but not of TBP
(not shown), allowed the speci¢c interaction between Tat and
CDK9 (Table 2), as shown previously [15], demonstrating that
the experimental system is capable of detecting interaction of
three proteins. However, the possibility existed that a quater-
nary complex is formed, where Sp1 does not directly bind
CycT1 (bound to Tat) or CDK9, but contacts the composite
contour created by the Tat/CycT1/CDK9 complex. To test
this hypothesis, the yeast three-protein system was expanded
to include a fourth protein for detecting quaternary complex
formation. Still, after transformation of yeast cells with plas-
mids encoding Tat and Sp1 hybrids plus CycT1 and CDK9 in
a non-fused form, no expression of the L-Gal reporter gene
was detected (Table 2). Therefore, we conclude that also the
CycT1/CDK9 complex is not able to mediate Tat^Sp1 inter-
action.
4. Discussion
We recently provided evidence that the HIV-1 Tat protein
and the Sp1 cellular transcription factor do not directly inter-
act either in vitro or in vivo [8], suggesting that the synergy
between Tat and Sp1 cannot be simply explained by a phys-
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Fig. 1. In vitro binding assay between MBP-Tat and recombinant human Sp1 in the presence of HeLa cell nuclear extracts (NE). Supernatants
derived from the incubation of puri¢ed MBP-Tat and Sp1 (lane 2), MBP-Tat and Sp1 with NE (lane 3), or MBP-Tat alone with NE (lane 4)
were analysed by Western blot using anti-Tat (A) or anti-Sp1 antibodies (B). As internal controls for Western blot, MBP-Tat or Sp1 were also
included (lane 1). The positions of MBP-Tat and Sp1 proteins and the molecular masses (in kDa) of the markers are indicated on the right
and left, respectively.
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ical interaction. Most likely, the functional interaction be-
tween Tat and Sp1 relies on a more complex interplay be-
tween viral and cellular factors. Indeed, a number of cellular
proteins have been reported to interact with Tat and/or Sp1
[9^22]. Any of these proteins or other unknown cellular pro-
tein(s) could indirectly mediate Tat^Sp1 interaction. More-
over, the possibility also existed that binding of HIV-1 Tat
with Sp1 could be promoted by other virus-encoded mole-
cule(s), i.e. TAR RNA or other HIV-1 protein(s). The
HIV-1 virion-associated protein (Vpr), for example, has been
shown to interact both with Tat [30] and with Sp1 [31].
Therefore, to investigate the latter possibility, in vitro bind-
ing assays between Tat and Sp1 in the presence of nuclear
extracts from uninfected cells were performed. We showed
that addition of HeLa cell nuclear extracts to puri¢ed Tat
and Sp1 proteins allows the formation of a Tat/Sp1 complex,
demonstrating that a molecule(s) present in mammalian nuclei
is indeed necessary and su⁄cient to mediate Tat^Sp1 interac-
tion.
Looking for a cellular partner(s) which could bridge Tat
and Sp1, TBP appeared particularly interesting as a candi-
date. Some reports have shown that Tat directly binds,
through its activation domain, human TBP [10,11]. The func-
tional relevance of Tat^TBP interaction for trans-activation of
HIV-1 gene expression still remains unclear, even though it
has been reported that Tat activity is stimulated when TBP is
overexpressed [11]. Noteworthy, Sp1 also interacts with TBP
[8,17], making conceivable the idea that TBP may mediate the
interaction between Tat and Sp1. Supporting this hypothesis,
it has recently been shown that the correct spatial arrange-
ment among TAR, Sp1-binding sites and TATA motif cru-
cially in£uences HIV-1 expression, suggesting that Tat, Sp1
and TBP must contact each other for optimal expression and
replication of HIV-1 [32]. However, TBP is not able to bridge
Tat and Sp1, as shown by the yeast three-protein experiments.
The inability of TBP to interact simultaneously with both Tat
and Sp1 could be explained by the fact that both Tat and Sp1
bind the C-terminal conserved domain of human TBP [10,17],
raising the possibility that they may compete in TBP binding.
Noteworthy, Sp1 does not bind to yeast TBP [17] and does
not stimulate transcription in S. cerevisiae [33]. In addition,
yeast TBP does not physically or functionally interact with
HIV-1 Tat [10], suggesting that yeast TBP does not interfere
with human TBP in these experiments.
Another potential candidate for bridging Tat and Sp1 could
be the CycT1/CDK9 complex. CycT1 was recently reported to
interact with the activation domain of Tat and with the pro-
tein kinase CDK9, enhancing the a⁄nity of Tat for TAR
RNA [15]. The interaction of Tat with CycT1/CDK9 and
TAR ensures hyperphosphorylation of the carboxy-terminal
domain of RNA polymerase II holoenzyme by CDK9, thus
promoting transcriptional elongation of the nascent viral
mRNA [15,29]. Since recent results showed that Sp1 interacts
with a cyclin (cyclin A) and can be phosphorylated by a cy-
clin-associated kinase, which modulates its trans-activating
activity [34], one could assume that the interaction between
Tat and CDK9, or Tat and the CycT1/CDK9 complex, has
the role to bring the protein kinase in proximity of Sp1,
bound to the HIV-1 LTR. This could allow Sp1 phosphory-
lation without direct contact between Tat and Sp1. Analyses
of Tat interaction with the CycT1/CDK9 complex by means
of the yeast two- and three-hybrid system show that this in-
teraction occurs through a physical contact only between Tat
and the cyclin T1 component, as reported [15,29], since CDK9
does not interact with Tat. Interestingly, we observed that
CycT1 dimerises. This ¢nding implies that the Tat/CycT1/
Table 2
Analysis of Tat^Sp1 interaction in the presence of TBP, CycT1, CDK9 and CycT1/CDK9 complex by the yeast multi-protein system
Hybrid Unfused protein(s) L-Gal expressiona
DNA-binding domain fusion Activation domain fusion
LexA-Tat GAD-Sp1 3
Tat-LexA GAD-Sp1 Q
LexA-Sp1 GAD-Tat 3
Sp1-LexA GAD-Tat 3
LexA-Tat GAD-Sp1 TBP 3
Tat-LexA GAD-Sp1 TBP Q
LexA-Sp1 GAD-Tat TBP 3
Sp1-LexA GAD-Tat TBP 3
LexA-Tat GAD-Sp1 CycT1 3
Tat-LexA GAD-Sp1 CycT1 Q
LexA-Sp1 GAD-Tat CycT1 3
Sp1-LexA GAD-Tat CycT1 3
LexA-Tat GAD-Sp1 CDK9 3
Tat-LexA GAD-Sp1 CDK9 Q
LexA-Sp1 GAD-Tat CDK9 3
Sp1-LexA GAD-Tat CDK9 3
LexA-Tat GAD-Sp1 CycT1/CDK9 3
Tat-LexA GAD-Sp1 CycT1/CDK9 Q
LexA-Sp1 GAD-Tat CycT1/CDK9 3
Sp1-LexA GAD-Tat CycT1/CDK9 3
LexA-Tat GAD-CDK9 CycT1 +
Tat-LexA GAD-CDK9 CycT1 +
LexA-CDK9 GAD-Tat CycT1 +
The yeast multi-protein assay was used to determine whether the interaction between Tat and Sp1 requires TBP, CycT1, CDK9 or CycT1/
CDK9 complex as a bridging partner, as described in Section 2. Ternary interaction among Tat/CycT1/CDK9 was assayed as a positive con-
trol.
a(+) Strong blue colour detected after 3^5 h incubation; ( Q ) light blue colour detected after 8^12 h incubation; (3) no signal detected after
24 h incubation.
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CDK9 complex is not ternary, as previously suggested [15],
but quaternary or even of higher order, since also Tat can
dimerise [35].
Our results with the yeast multi-protein system indicate that
neither CycT1 and CDK9 alone or the CycT1/CDK9 complex
can mediate Tat^Sp1 interaction. Thus, the protein(s) that
bridge Tat and Sp1 are still to be identi¢ed. However, the
yeast multi-protein system we developed allows simple and
rapid detection of interactions among up to four protein part-
ners, and therefore will be a useful tool to further dissect the
protein^protein interactions involved in the assembly of tran-
scription complexes at the HIV-1 LTR or, in general, any
relevant protein^protein interaction in multi-protein com-
plexes.
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